CN104918956A - 与egfr结合的抗原结合蛋白 - Google Patents

与egfr结合的抗原结合蛋白 Download PDF

Info

Publication number
CN104918956A
CN104918956A CN201380038496.5A CN201380038496A CN104918956A CN 104918956 A CN104918956 A CN 104918956A CN 201380038496 A CN201380038496 A CN 201380038496A CN 104918956 A CN104918956 A CN 104918956A
Authority
CN
China
Prior art keywords
seq
egfr
antibody
referred
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380038496.5A
Other languages
English (en)
Chinese (zh)
Inventor
周贺钺
兰迪·加斯特沃特
芭芭拉·A·斯旺森
约翰·迪克森·葛雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of CN104918956A publication Critical patent/CN104918956A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201380038496.5A 2012-05-17 2013-05-13 与egfr结合的抗原结合蛋白 Pending CN104918956A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648391P 2012-05-17 2012-05-17
US61/648,391 2012-05-17
PCT/US2013/040827 WO2013173255A2 (en) 2012-05-17 2013-05-13 Antigen binding proteins that bind egfr

Publications (1)

Publication Number Publication Date
CN104918956A true CN104918956A (zh) 2015-09-16

Family

ID=49581478

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380038496.5A Pending CN104918956A (zh) 2012-05-17 2013-05-13 与egfr结合的抗原结合蛋白

Country Status (7)

Country Link
US (1) US9944707B2 (enExample)
EP (1) EP2850105A4 (enExample)
JP (1) JP6441792B2 (enExample)
CN (1) CN104918956A (enExample)
CA (1) CA2872018A1 (enExample)
HK (1) HK1208474A1 (enExample)
WO (1) WO2013173255A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069570A (zh) * 2015-12-16 2018-12-21 默沙东公司 抗lag3抗体和抗原结合片段

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
JP2018513856A (ja) * 2015-04-08 2018-05-31 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｃｄ１２３に結合する抗体治療剤
MA43660A (fr) 2016-01-22 2018-11-28 Adimab Llc Anticorps anti-facteur xi de coagulation
HUE058745T2 (hu) * 2016-04-27 2022-09-28 Green Cross Corp Hatóanyagként epidermális növekedési faktor receptorhoz specifikusan kötõdõ antitestet tartalmazó gyógyászati készítmény rák áttételének gátlására
TWI752964B (zh) 2016-06-14 2022-01-21 美商默沙東藥廠 抗凝血因子ｘｉ抗體
JP7302028B2 (ja) * 2019-06-04 2023-07-03 アカデミア シニカ 上皮成長因子受容体を標的とするリガンド、及び腫瘍を治療するための組成物
WO2021035096A1 (en) * 2019-08-20 2021-02-25 Kumquat Biosciences Inc. Compositions and methods for targeting cellular molecules
EP4347643A4 (en) * 2021-05-27 2025-09-17 Us Gov Veterans Affairs HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO STREPTOLYSIN O AND METHODS OF USE
EP4473018A2 (en) * 2022-02-04 2024-12-11 Vivasor, Inc. Antigen binding proteins that bind b7-h3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1610695A (zh) * 2001-06-13 2005-04-27 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
CN101115773A (zh) * 2005-02-07 2008-01-30 格黎卡特生物技术股份公司 结合egfr的抗原结合分子，编码它的载体，及其应用
CN101233155A (zh) * 2004-03-19 2008-07-30 伊姆克罗尼系统公司 人抗表皮生长因子受体抗体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL181342B1 (pl) 1994-03-17 2001-07-31 Merck Patent Gmbh Jednolancuchowe anty-EGFR Fv i przeciwciala anty-EGFR, czasteczka DNA, sposoby wytwarzania jednolancuchowego przeciwciala anty-EGFR i przeciwciala anty-EGFR oraz kompozycja farmaceutyczna PL PL PL PL PL PL PL
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) * 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
DE60042693D1 (de) 1999-08-27 2009-09-17 Genentech Inc Dosierung für die behandlung mit anti erbb2-antikörpern
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
RU2402569C2 (ru) 2004-03-19 2010-10-27 Имклоун Элэлси Человеческие антитела к рецептору эпидермального фактора роста
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
ATE461220T1 (de) * 2005-11-12 2010-04-15 Lilly Co Eli Anti-egfr-antikörper
WO2009012181A2 (en) 2007-07-13 2009-01-22 Ventana Medical Systems, Inc. Method of identifying diagnostic reagents
MX2011003133A (es) 2008-09-26 2011-04-21 Roche Glycart Ag Anticuerpos biespecificos anti-egfr/anti-igf-1r.
US20110287112A1 (en) 2009-01-30 2011-11-24 Ono Pharmaceutical Co., Ltd. Prostate cancer progression inhibitor and progression inhibition method
CA2754646A1 (en) 2009-03-31 2010-10-07 Roche Glycart Ag Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
US8658175B2 (en) 2009-10-28 2014-02-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
JP5818003B2 (ja) 2009-11-18 2015-11-18 国立大学法人東北大学 ヒト型化抗ｅｇｆｒ抗体可変領域の高機能性変異体
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
EP2632490A4 (en) 2010-10-29 2014-10-22 Immunogen Inc NOVEL MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
TWI443108B (zh) 2011-12-28 2014-07-01 Ind Tech Res Inst 抗人類表皮生長因子受體抗體及其應用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1610695A (zh) * 2001-06-13 2005-04-27 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
CN101233155A (zh) * 2004-03-19 2008-07-30 伊姆克罗尼系统公司 人抗表皮生长因子受体抗体
CN101115773A (zh) * 2005-02-07 2008-01-30 格黎卡特生物技术股份公司 结合egfr的抗原结合分子，编码它的载体，及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069570A (zh) * 2015-12-16 2018-12-21 默沙东公司 抗lag3抗体和抗原结合片段

Also Published As

Publication number Publication date
JP6441792B2 (ja) 2018-12-19
US9944707B2 (en) 2018-04-17
EP2850105A4 (en) 2016-03-16
WO2013173255A2 (en) 2013-11-21
JP2015518827A (ja) 2015-07-06
HK1208474A1 (en) 2016-03-04
CA2872018A1 (en) 2013-11-21
EP2850105A2 (en) 2015-03-25
US20130309233A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
CN105683217B (zh) 与pd-1结合的抗原结合蛋白
CN104736168B (zh) 与pd-l1结合的抗原结合蛋白
CN109715821B (zh) 与pd-l1结合的抗原结合蛋白
CN105050618B (zh) 与c-Met结合的抗原结合蛋白
CN105120890B (zh) 与ErbB3结合的抗原结合蛋白
CN104918956A (zh) 与egfr结合的抗原结合蛋白
JP2015518827A5 (enExample)
CN104603151A (zh) 与dll-4结合的抗原结合蛋白
CN104411332B (zh) 与vegfr2结合的全人抗体
CN104994872B (zh) 与igf1r结合的抗原结合蛋白
HK1238648B (zh) 與pd-1結合的抗原結合蛋白

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150916